Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

Study Overview

This is a multicenter, multi-arm, international, phase Ib, 3 x 3 dose-escalation study with an initial phase I followed by an expansion phase. The primary objective of the phase Ib is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and dose limiting toxicity (DLT) of various combinations of pembrolizumab, pralatrexate and decitabine.

Study Description

Novel immuno-epigenetic based platform for patients with peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL): an international phase Ib study of pembrolizumab combined with decitabine and/or pralatrexate

  • Identifier: NCT03240211
  • Protocol Number: 18-363
  • Principal Investigator: Salvia Jain

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000